Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayJun 06, 2017 12:30 pm

ITUS Corp. (NASDAQ: ITUS) Starts Presentation at LD Micro 2017 Invitational

ITUS (NASDAQ: ITUS) funds, develops, acquires and licenses emerging technologies in the areas of biotechnology. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. It has a collaborative research agreement with The Wistar Institute for the development and validation of Cchek. The company was formerly known as CopyTele, Inc. and changed its name to ITUS Corporation in September 2014. ITUS Corporation was founded in 1982 and is based in Los Angeles, California. For more information, visit the company's website at…

Continue Reading

TuesdayJun 06, 2017 12:30 pm

SilverSun Technologies, Inc. (NASDAQ: SSNT) Starts Presentation at LD Micro 2017 Invitational

SilverSun Technologies (NASDAQ: SSNT) operates as a business application, technology and consulting company. The company resells enterprise resource planning financial accounting solution that provides various functions related to accounting, including financial reporting, accounts payable and accounts receivable, and inventory management, as well as offers training, technical support, and professional services. It also publishes and markets MAPADOC, an electronic data interchange software through a network of resellers. In addition, the company resells warehouse management system software, which controls the movement and storage of materials within an operation, and processes the related transactions. Further, it provides customer relationship management and business intelligence…

Continue Reading

TuesdayJun 06, 2017 12:30 pm

Arch Therapeutics, Inc. (ARTH) Starts Presentation at LD Micro 2017 Invitational

Arch Therapeutics (OTC: ARTH) is a life science medical device company that develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. Its primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics was founded in 2006 and is based in Framingham, Massachusetts. For more information, visit the company's website at www.archtherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news…

Continue Reading

TuesdayJun 06, 2017 12:00 pm

Fision Corp. (FSSN) Starts Presentation at LD Micro 2017 Invitational

Fision (OTC: FSSN) develops and commercializes cloud-based software platform. The company’s Fision marketing software centrally collects, stores, prioritizes, organizes, streamlines, integrates and distributes various digital marketing assets of its customers, including videos, images, logos and other brand materials, presentations, social content and other material marketing assets. It serves various industries, including banks and other financial institutions, insurance companies, hotels and other hospitality enterprises, healthcare and fitness companies, software and other technology companies, telecommunications companies, and other companies. The company licenses its proprietary software platform primarily through direct sales and independent national sales agencies. For more information, visit the company's website…

Continue Reading

TuesdayJun 06, 2017 12:00 pm

NeuroMetrix, Inc. (NASDAQ: NURO) Starts Presentation at LD Micro 2017 Invitational

NeuroMetrix (NASDAQ: NURO) is a commercial-stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several…

Continue Reading

TuesdayJun 06, 2017 12:00 pm

Sigma Labs, Inc. (NASDAQ:SGLB) Starts Presentation at LD Micro 2017 Invitational

Sigma Labs (NASDAQ: SGLB) provides quality assurance software under the PrintRite3D® brand and is a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. The company’s manufacturing and materials technologies and R&D solutions are designed for first-tier integrators like Boeing, GE Aviation, Honeywell Aerospace, and other commercial firms. Sigma Labs has current contracts with Federal Government and private industry clients to develop technologies from their conception through the design, building, and testing of prototype systems by integrating sensing, software, materials, and manufacturing technology risk-reduction solutions. For more information, visit the company's…

Continue Reading

TuesdayJun 06, 2017 12:00 pm

Vitality Biopharma (VBIO) Starts Presentation at LD Micro 2017 Invitational

Vitality Biopharma (OTC: VBIO) focuses on the development of cannabinoids for the treatment of neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis in the United States. Its products in the pipeline include Cannabosides - VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides - VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. For more information, visit the company's…

Continue Reading

TuesdayJun 06, 2017 12:00 pm

Stony Hill Corp. (STNY) Starts Presentation at LD Micro 2017 Invitational

Stony Hill Corp. (OTC: STNY) is a vertically integrated company that focuses on various areas of the cannabis industry. The company explores and operates in the consumer, health and wellness, recreational, medical, media, and nutraceutical industries. Stony Hill Corp. is based in Los Angeles, California. For more information, visit the company's website at www.stonyhillcorp.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an…

Continue Reading

TuesdayJun 06, 2017 11:30 am

Viking Therapeutics (NASDAQ: VKTX) Starts Presentation at LD Micro 2017 Invitational

Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease Type Ia, and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy. For more information,…

Continue Reading

TuesdayJun 06, 2017 11:30 am

Caladrius Biosciences, Inc. (NASDAQ: CLBS) Starts Presentation at LD Micro 2017 Invitational

Caladrius Biosciences (NASDAQ: CLBS) is advancing a proprietary platform technology for immunomodulation by pioneering the use of T regulatory cells as an innovative therapy for recent onset Type 1 diabetes. Product candidate CLBS03 is the subject of an ongoing phase 2 clinical trial (The Sanford Project: T-Rex study) in collaboration with Sanford Research, and has been granted Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration, as well as Advanced Therapeutic Medicinal Product classification by the European Medicines Agency. The company’s subsidiary, PCT, is a well-known development and manufacturing partner exclusively focused on the cell therapy…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000